Software for Modeling Delivery and Penetration of Antibody Conjugates


The National Cancer Institute (NCI) seeks parties to license software for modeling the targeted delivery of anti-cancer agents in solid tumors.

The software models the permeability and concentration of intravenously administered antibody anti-cancer agent conjugates in solid tumors.  The models can be used to determine optimal dosing regimen of a therapeutic in a particular cancer type.  Thirty factors that affect delivery rates and efficiencies are analyzed as variables in generating the models.



Potential Commercial Applications: Competitive Advantages:
  • Drug design
  • Combination therapy
  • Personalized medicine
 
  • Accurate permeability modeling of anti-cancer therapeutics.


Development Stage:
Prototype

Inventors:

Byungkook Lee (NCI)  ➽ more inventions...


Intellectual Property:

Publications:
R.K. Jain et al. Delivery of molecular and cellular medicine to solid tumors. PMID 11259838
G.M. Thurber et al. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. PMID 18541331
Y. Pak et al. Antigen shedding may improve efficiencies for delivery of antibody-based anticancer agents in solid tumors. PMID: 22562466
K.C. Chen et al. Modeling recombinant immunotoxin efficacies in solid tumors. PMID: 18183487

Collaboration Opportunity:

Licensing only


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-060-2012
Updated: Jun 7, 2018